Status:
COMPLETED
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment
Lead Sponsor:
Tanta University
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to monitor the levels of soluble L-selectin (sCD62L) and secreted protein acidic rich in cysteine (SPARC) in chronic phase chronic myeloid leukemia (CP-CML) patients at baseline and af...
Detailed Description
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder characterized by the reciprocal t (9:22) chromosomal translocation. This rearrangement produces abnormal chromosome called Ph...
Eligibility Criteria
Inclusion
- Both sexes.
- Newly diagnosed patient with chronic phase, Philadelphia chromosome positive (Ph+) CML.
- Age ≥ 18 years.
Exclusion
- Patients in blastic or accelerated phase of chronic myeloid leukemia.
- Previous treatment with Imatinib.
- Pregnancy and lactation.
- Severe hepatic dysfunction.
- Kidney dysfunction.
- Intolerant or incompliant to imatinib.
Key Trial Info
Start Date :
April 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 28 2021
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT05387330
Start Date
April 1 2018
End Date
December 28 2021
Last Update
May 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, Egypt, 31511